LEQ-506


CAS No. : 1204975-42-7

LEQ-506,1204975-42-7
Product Details
For research use only. Not Intended for Therapeutic Use!
Cat No:I007643
Synonyms:LEQ506; LEQ-506; LEQ 506; NPVLEQ 506; NPVLEQ-506; NPV LEQ506; NPVLEQ506.;(R)-2-(5-(4-(6-benzyl-4,5-dimethylpyridazin-3-yl)-2-methylpiperazin-1-yl)pyrazin-2-yl)propan-2-ol
Molecular Formula:C25H32N6O
Molecular Weight:432.572
Target:Smoothened antagonist
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.

refresh
Appearance:Solid powder
Purity:98%
Cat No:I007643
Cas No:1204975-42-7
Product-Name:LEQ-506
IUPAC Name:2-[5-[(2R)-4-(6-benzyl-4,5-dimethylpyridazin-3-yl)-2-methylpiperazin-1-yl]pyrazin-2-yl]propan-2-ol
InChI:InChI=1S/C25H32N6O/c1-17-16-30(11-12-31(17)23-15-26-22(14-27-23)25(4,5)32)24-19(3)18(2)21(28-29-24)13-20-9-7-6-8-10-20/h6-10,14-15,17,32H,11-13,16H2,1-5H3/t17-/m1/s1
InChIKey:POERAARDVFVDLO-QGZVFWFLSA-N
SMILES:CC1CN(CCN1C2=NC=C(N=C2)C(C)(C)O)C3=NN=C(C(=C3C)C)CC4=CC=CC=C4
LEQ506, also known as NPV-LEQ506, is a n orally bioavailable small-molecule Smoothened (Smo) antagonist with potential antineoplastic activity. Smoothened antagonist LEQ506 selectively binds to the Hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway, thereby inhibiting tumor cell growth. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Dysregulated activation of Hh pathway signaling and uncontrolled cellular proliferation, as is observed in a variety of cancers, may be associated with mutations in the Hh-ligand cell surface receptor Smo. Check for active clinical trials or closed clinical trials using this agent.

1:Peukert S, He F, Dai M, Zhang R, Sun Y, Miller-Moslin K, McEwan M, Lagu B, Wang K, Yusuff N, Bourret A, Ramamurthy A, Maniara W, Amaral A, Vattay A, Wang A, Guo R, Yuan J, Green J, Williams J, Buonamici S, Kelleher JF 3rd, Dorsch M. Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened. ChemMedChem. 2013 Aug;8(8):1261-5. doi: 10.1002/cmdc.201300217. Epub 2013 Jul 2. PubMed PMID: 23821351.
2:Tang JY, Marghoob AA. Emerging treatments and signaling pathway inhibitors. Semin Cutan Med Surg. 2011 Dec;30(4 Suppl):S14-8. doi: 10.1016/j.sder.2011.11.002. Review. PubMed PMID: 22177102.
Recommended Products
  • CAS No. :1433278-33-1
    Product Name:

    4-[4-(Dimethylamino)-1-oxobutyl]-3-(hydroxymethyl)benzonitrile

    Cat No: R043062 View details
  • CAS No. :7495-37-6
    Product Name:

    3,6-Dimethyl-fluorene

    Cat No: R043063 View details
  • CAS No. :NA
    Product Name:

    4-[4-(Dimethylamino)-1-oxobutyl]-3-(hydroxymethyl)benzonitrile-D6

    Cat No: R043064 View details
  • CAS No. :93413-61-7
    Product Name:

    1-(1-(4-(Benzyloxy)phenyl)-2-(dimethylamino)ethyl)cyclohexanol

    Cat No: R043065 View details